| 摘要: |
| 目的：研究抗癌消水散对人胃癌小鼠腹腔移植阳虚模型的影响。方法：采用腹腔注射人胃癌细胞MGC803及冰水建立人胃癌小鼠腹腔移植阳虚模型，将造模成功的50只小鼠分为模型组及抗癌消水散低、中、高剂量组，每组各10只，另取10只正常小鼠为对照组。干预30 d后评价阳虚症状积分，测定血清中促肾上腺皮质激素（ACTH）、皮质醇（CORT）、三碘甲状腺原氨酸（T3）、甲状腺素（T4）、促甲状腺激素（TSH）含量及B7-1、B7-2、CD28、胞毒性T淋巴细胞相关抗原-4（CTLA-4）含量，检测腹膜组织中B7-1（CD80）、B7-2（CD86）、CD28 mRNA、CTLA-4 mRNA及转化生长因子-β1（TGF-β1）、白细胞介素-10（IL-10）含量，观察腹水量、瘤体积、瘤重。结果：与正常组比较，模型组阳虚症状积分显著增加，血清ACTH、CORT、T3、T4、TSH水平显著降低，差异均有统计学意义（P<0.01）。抗癌消水散低、中、高剂量组小鼠腹水量、瘤体积、瘤重，血清中B7-1、B7-2、CD28、CTLA-4含量，腹膜组织中B7-1、B7-2、CD28 mRNA、CTLA-4 mRNA及TGF-β1、IL-10含量与模型组比较，差异均有统计学意义（P<0.05）；上述指标低、中、高剂量组组间比较，差异亦有统计学意义（P<0.05），以高剂量组改善为最佳。结论：抗癌消水散具有抗人胃癌小鼠移植阳虚模型瘤恶性腹水的作用，这可能与抑制CTLA-4表达，促进T细胞激活，改善机体免疫抑制及腹腔免疫微环境有关。 |
| 关键词: 人胃癌小鼠腹腔移植模型 阳虚证 抗癌消水散 实验研究 |
| DOI： |
|
|
| Intervention effect of Kang'ai Xiaoshui powder on a mouse abdominal xenograft model of human gastric cancer with Yang deficiency |
| PENG Yinhua,GONG Hui,ZHAO Ye |
| (The Affiliated Hospital of Hunan Academy of Chinese Medicine，Changsha 410006，Hunan，China) |
| Abstract: |
| Objective：To investigate the effect of Kang'ai Xiaoshui powder on a mouse abdominal xenograft model of human gastric cancer with Yang deficiency.Methods：A mouse abdominal xenograft model of human gastric cancer with Yang deficiency was established by intraperitoneal injection of human gastric cancer MGC803 cells and ice water，and after successful modeling，50 mice were divided into model group and low-，middle-，and high-dose Kang'ai Xiaoshui powder groups，with 10 mice in each group.In addition，10 normal mice were selected as control group.Related indices were measured and assessed after intervention for 30 days，including the symptom score of Yang deficiency，the amount of ascites，tumor volume，and tumor weight，as well as the serum levels of adrenocorticotropic hormone (ACTH)，corticosterone (CORT)，triiodothyronine (T3)，thyroxine (T4)，thyroid stimulating hormone (TSH)，B7-1，B7-2，CD28，and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the levels of B7-1 (CD80)，B7-2 (CD86)，CD28 mRNA，CTLA-4 mRNA，transforming growth factor-beta 1 (TGF-β1)，and interleukin-10 (IL-10) in peritoneal tissue.Results：Compared with the control group，the model group had a significant increase in the symptom score of Yang deficiency and significant reductions in the serum levels of ACTH，CORT，T3，T4，and TSH (P<0.01).There were significant differences between the low-，middle-，and high-dose Kang'ai Xiaoshui powder groups and the model group in the amount of ascites，tumor volume，tumor weight，the serum levels of B7-1，B7-2，CD28，and CTLA-4，and the levels of B7-1，B7-2，CD28 mRNA，CTLA-4 mRNA，TGF-β1，and IL-10 in peritoneal tissue (P<0.05).There were also significant differences in the above indices between the low-，middle-，and high-dose Kang'ai Xiaoshui powder groups (P<0.05)，and the high-dose group showed the greatest improvement in these indices.Conclusion：Kang'ai Xiaoshui powder exerts a therapeutic effect on malignant ascites in the mouse abdominal xenograft model of human gastric cancer with Yang deficiency，possibly by inhibiting the expression of CTLA-4，promoting T cell activation，and improving immunosuppression and immune microenvironment in abdominal cavity. |
| Key words: mouse abdominal xenograft model of human gastric cancer Yang deficiency Kang'ai Xiaoshui powder experimental study |
